CALC vs. CARA, GOSS, OMER, ELYM, GTHX, OVID, HOWL, SBTX, CDT, and RENB
Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Cara Therapeutics (CARA), Gossamer Bio (GOSS), Omeros (OMER), Eliem Therapeutics (ELYM), G1 Therapeutics (GTHX), Ovid Therapeutics (OVID), Werewolf Therapeutics (HOWL), Silverback Therapeutics (SBTX), Conduit Pharmaceuticals (CDT), and Renovaro (RENB). These companies are all part of the "pharmaceutical preparations" industry.
CalciMedica (NASDAQ:CALC) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.
In the previous week, Cara Therapeutics had 3 more articles in the media than CalciMedica. MarketBeat recorded 6 mentions for Cara Therapeutics and 3 mentions for CalciMedica. CalciMedica's average media sentiment score of 1.18 beat Cara Therapeutics' score of 0.76 indicating that CalciMedica is being referred to more favorably in the media.
CalciMedica has higher earnings, but lower revenue than Cara Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
CalciMedica has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. CalciMedica's return on equity of -143.95% beat Cara Therapeutics' return on equity.
44.7% of Cara Therapeutics shares are owned by institutional investors. 53.3% of CalciMedica shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
CalciMedica has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Cara Therapeutics received 658 more outperform votes than CalciMedica when rated by MarketBeat users. However, 100.00% of users gave CalciMedica an outperform vote while only 75.03% of users gave Cara Therapeutics an outperform vote.
CalciMedica currently has a consensus target price of $18.67, suggesting a potential upside of 228.64%. Cara Therapeutics has a consensus target price of $11.12, suggesting a potential upside of 1,612.35%. Given Cara Therapeutics' higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than CalciMedica.
Summary
CalciMedica beats Cara Therapeutics on 10 of the 16 factors compared between the two stocks.
Get CalciMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CalciMedica Competitors List
Related Companies and Tools
